Skip to Content

Additional Content In This Section

STRATIFY-2

Objective

Status

Enrollment complete

Condition

Multiple Sclerosis (MS)

Description

JVC Antibody program in patients with relapsing MS or considering treatment with Tysabri®. Requires blood sample collection at enrollment and annually thereafter for two years

Purpose

To better understand whether antibodies to JCV may be used to predict whether a patient is at higher or lower risk for developing Progressive Multifocal Encephalopathy (PML)

Phase

IV

Key Inclusion Criteria

Patients with relapsing MS receiving commercial Tysabri and patients being considered for such treatment.

Key Exclusion Criteria

Patients participating in any other Tysabri clinical trial or study sponsored by Biogen Idec or Elan may not participate in this study.

ClinicalTrials.gov Identifier

NCT01070836

IRB Protocol Number
101JC402
Principal Investigator(s)
Mathew Roller, MD

Clinical Trial Categories

  • Neurology
Sponsor(s)
Biogen Idec
Contact
Renee Hendrickson, RN CCRC at 701-780-1694
or rhendrickson@altru.org